Clinical Trial ResultsPositive updated data from its P2b trial evaluating OST-HER2 in recurrent osteosarcoma was reported, showing promising event-free survival rates.
Financial OutlookThe positive outcome and potential for filing for accelerated approval led to a lower revenue risk adjustment and an increased 12-month price target.
Regulatory ApprovalOST-HER2 holds FDA Orphan, Fast Track, and Rare Pediatric Disease designations, making it eligible for a priority review voucher, if approved.